Cargando…

Trimetazidine attenuates pressure overload-induced early cardiac energy dysfunction via regulation of neuropeptide Y system in a rat model of abdominal aortic constriction

BACKGROUND: Metabolism remodeling has been recognized as an early event following cardiac pressure overload. However, its temporal association with ventricular hypertrophy has not been confirmed. Moreover, whether trimetazidine could favorably affect this process also needs to be determined. The aim...

Descripción completa

Detalles Bibliográficos
Autores principales: Chen, Ailan, Li, Wanglin, Chen, Xinyu, Shen, Yuechun, Dai, Wenjun, Dong, Qi, Li, Xinchun, Ou, Caiwen, Chen, Minsheng
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2016
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5112876/
https://www.ncbi.nlm.nih.gov/pubmed/27855650
http://dx.doi.org/10.1186/s12872-016-0399-8
_version_ 1782468093763649536
author Chen, Ailan
Li, Wanglin
Chen, Xinyu
Shen, Yuechun
Dai, Wenjun
Dong, Qi
Li, Xinchun
Ou, Caiwen
Chen, Minsheng
author_facet Chen, Ailan
Li, Wanglin
Chen, Xinyu
Shen, Yuechun
Dai, Wenjun
Dong, Qi
Li, Xinchun
Ou, Caiwen
Chen, Minsheng
author_sort Chen, Ailan
collection PubMed
description BACKGROUND: Metabolism remodeling has been recognized as an early event following cardiac pressure overload. However, its temporal association with ventricular hypertrophy has not been confirmed. Moreover, whether trimetazidine could favorably affect this process also needs to be determined. The aim of the study was to explore the temporal changes of myocardial metabolism remodeling following pressure-overload induced ventricular hypertrophy and the potential favorable effect of trimetazidine on myocardial metabolism remodeling. METHODS: A rat model of abdominal aortic constriction (AAC)-induced cardiac pressure overload was induced. These rats were grouped as the AAC (no treatment) or TMZ group according to whether oral trimetazidine (TMZ, 40 mg/kg/d, for 5 days) was administered. Changes in cardiac structures were sequentially evaluated via echocardiography. The myocardial ADP/ATP ratio was determined to reflect the metabolic status, and changes in serum neuropeptide Y systems were evaluated. RESULTS: Myocardial metabolic disorder was acutely induced as evidenced by an increased ADP/ATP ratio within 7 days of AAC before the morphological changes in the myocardium, accompanied by up-regulation of serum oxidative stress markers and expression of fetal genes related to hypertrophy. Moreover, the serum NPY and myocardial NPY-1R, 2R, and 5R levels were increased within the acute phase of AAC-induced cardiac pressure overload. Pretreatment with TMZ could partly attenuate myocardial energy metabolic homeostasis, decrease serum levels of oxidative stress markers, attenuate the induction of hypertrophy-related myocardial fetal genes, inhibit the up-regulation of serum NPY levels, and further increase the myocardial expression of NPY receptors. CONCLUSIONS: Cardiac metabolic remodeling is an early change in the myocardium before the presence of typical morphological ventricular remodeling following cardiac pressure overload, and pretreatment with TMZ may at least partly reverse the acute metabolic disturbance, perhaps via regulation of the NPY system.
format Online
Article
Text
id pubmed-5112876
institution National Center for Biotechnology Information
language English
publishDate 2016
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-51128762016-11-25 Trimetazidine attenuates pressure overload-induced early cardiac energy dysfunction via regulation of neuropeptide Y system in a rat model of abdominal aortic constriction Chen, Ailan Li, Wanglin Chen, Xinyu Shen, Yuechun Dai, Wenjun Dong, Qi Li, Xinchun Ou, Caiwen Chen, Minsheng BMC Cardiovasc Disord Research Article BACKGROUND: Metabolism remodeling has been recognized as an early event following cardiac pressure overload. However, its temporal association with ventricular hypertrophy has not been confirmed. Moreover, whether trimetazidine could favorably affect this process also needs to be determined. The aim of the study was to explore the temporal changes of myocardial metabolism remodeling following pressure-overload induced ventricular hypertrophy and the potential favorable effect of trimetazidine on myocardial metabolism remodeling. METHODS: A rat model of abdominal aortic constriction (AAC)-induced cardiac pressure overload was induced. These rats were grouped as the AAC (no treatment) or TMZ group according to whether oral trimetazidine (TMZ, 40 mg/kg/d, for 5 days) was administered. Changes in cardiac structures were sequentially evaluated via echocardiography. The myocardial ADP/ATP ratio was determined to reflect the metabolic status, and changes in serum neuropeptide Y systems were evaluated. RESULTS: Myocardial metabolic disorder was acutely induced as evidenced by an increased ADP/ATP ratio within 7 days of AAC before the morphological changes in the myocardium, accompanied by up-regulation of serum oxidative stress markers and expression of fetal genes related to hypertrophy. Moreover, the serum NPY and myocardial NPY-1R, 2R, and 5R levels were increased within the acute phase of AAC-induced cardiac pressure overload. Pretreatment with TMZ could partly attenuate myocardial energy metabolic homeostasis, decrease serum levels of oxidative stress markers, attenuate the induction of hypertrophy-related myocardial fetal genes, inhibit the up-regulation of serum NPY levels, and further increase the myocardial expression of NPY receptors. CONCLUSIONS: Cardiac metabolic remodeling is an early change in the myocardium before the presence of typical morphological ventricular remodeling following cardiac pressure overload, and pretreatment with TMZ may at least partly reverse the acute metabolic disturbance, perhaps via regulation of the NPY system. BioMed Central 2016-11-17 /pmc/articles/PMC5112876/ /pubmed/27855650 http://dx.doi.org/10.1186/s12872-016-0399-8 Text en © The Author(s). 2016 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Research Article
Chen, Ailan
Li, Wanglin
Chen, Xinyu
Shen, Yuechun
Dai, Wenjun
Dong, Qi
Li, Xinchun
Ou, Caiwen
Chen, Minsheng
Trimetazidine attenuates pressure overload-induced early cardiac energy dysfunction via regulation of neuropeptide Y system in a rat model of abdominal aortic constriction
title Trimetazidine attenuates pressure overload-induced early cardiac energy dysfunction via regulation of neuropeptide Y system in a rat model of abdominal aortic constriction
title_full Trimetazidine attenuates pressure overload-induced early cardiac energy dysfunction via regulation of neuropeptide Y system in a rat model of abdominal aortic constriction
title_fullStr Trimetazidine attenuates pressure overload-induced early cardiac energy dysfunction via regulation of neuropeptide Y system in a rat model of abdominal aortic constriction
title_full_unstemmed Trimetazidine attenuates pressure overload-induced early cardiac energy dysfunction via regulation of neuropeptide Y system in a rat model of abdominal aortic constriction
title_short Trimetazidine attenuates pressure overload-induced early cardiac energy dysfunction via regulation of neuropeptide Y system in a rat model of abdominal aortic constriction
title_sort trimetazidine attenuates pressure overload-induced early cardiac energy dysfunction via regulation of neuropeptide y system in a rat model of abdominal aortic constriction
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5112876/
https://www.ncbi.nlm.nih.gov/pubmed/27855650
http://dx.doi.org/10.1186/s12872-016-0399-8
work_keys_str_mv AT chenailan trimetazidineattenuatespressureoverloadinducedearlycardiacenergydysfunctionviaregulationofneuropeptideysysteminaratmodelofabdominalaorticconstriction
AT liwanglin trimetazidineattenuatespressureoverloadinducedearlycardiacenergydysfunctionviaregulationofneuropeptideysysteminaratmodelofabdominalaorticconstriction
AT chenxinyu trimetazidineattenuatespressureoverloadinducedearlycardiacenergydysfunctionviaregulationofneuropeptideysysteminaratmodelofabdominalaorticconstriction
AT shenyuechun trimetazidineattenuatespressureoverloadinducedearlycardiacenergydysfunctionviaregulationofneuropeptideysysteminaratmodelofabdominalaorticconstriction
AT daiwenjun trimetazidineattenuatespressureoverloadinducedearlycardiacenergydysfunctionviaregulationofneuropeptideysysteminaratmodelofabdominalaorticconstriction
AT dongqi trimetazidineattenuatespressureoverloadinducedearlycardiacenergydysfunctionviaregulationofneuropeptideysysteminaratmodelofabdominalaorticconstriction
AT lixinchun trimetazidineattenuatespressureoverloadinducedearlycardiacenergydysfunctionviaregulationofneuropeptideysysteminaratmodelofabdominalaorticconstriction
AT oucaiwen trimetazidineattenuatespressureoverloadinducedearlycardiacenergydysfunctionviaregulationofneuropeptideysysteminaratmodelofabdominalaorticconstriction
AT chenminsheng trimetazidineattenuatespressureoverloadinducedearlycardiacenergydysfunctionviaregulationofneuropeptideysysteminaratmodelofabdominalaorticconstriction